# Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

> **NCT02501603** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 72 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** afatinib
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT02501603
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-20
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501603, "Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer". Retrieved via MORVS 2026-10-06 from https://api.morvs.ai/clinical/NCT02501603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*